Residual Viremia is preceding viral blips and persistent low-level Viremia in treated HIV-1 patients

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Marije Hofstra, Laura ^a   Mudrikova, Tania ^a   Stam, Arjen J ^a   Otto, Sigrid ^a   Tesselaar, Kiki ^a   Nijhuis, Monique ^a   Wensing, Annemarie M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERSISTENT VIRUS INFECTION; RESIDUAL VIREMIA; RNA ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS VIRULENCE; BLOOD; COMPLICATION; GENETICS; HIV INFECTIONS; MIDDLE AGED; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84908638742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110749     Document Type: Article

References (39)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. Jama 308: 387-402.
2. European AIDS Clinical Society (2013) EACS Guidelines.
3. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Lowlevel viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 105: 3879-3884.
4. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathogens 3: 484-488.
5. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, et al. (2012) Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54: 724-732.
6. Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, et al. (2014) Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol 52: 517-523.
7. Lima V, Harrigan R, Montaner JS (2009) Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 51: 3-6.
8. Smit E, Bhattacharya S, Osman H, Taylor S (2009) Increased frequency of HIV-1 viral load blip rate observed after switching from roche cobas amplicor to cobas taqman assay. Journal of Acquired Immune Deficiency Syndromes 51: 364-365.
9. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. Jama 293: 817-829.
10. Lee PK, Kieffer TL, Siliciano RF, Nettles RE (2006) HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 57: 803-805.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
12. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H (2013) Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation. Clin Infect Dis.
13. Zoufaly A, Kiepe J, Hertling S, Hufner A, Degen O, et al. (2014) Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. HIV Med.
14. Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, et al. (2013) CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 63: 101-104.
15. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
16. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, et al. (2002) Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. Aids 16: 1967-1969.
17. Raboud JM, Rae S, Woods R, Harris M, Montaner JS (2002) Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. Aids 16: 1627-1632.
18. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG (2006) Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 7: 437-441.
19. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, et al. (2008) Determinants of virological failure after successful viral load suppression in firstline highly active antiretroviral therapy. Antivir Ther 13: 927-936.
20. Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, et al. (2012) Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One 7: e36673.
21. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, et al. (2011) Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 204: 515-520.
22. Swenson LC, Min JE, Woods CK, Cai E, Li JZ, et al. (2014) HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS.
23. Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, et al. (2014) Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment- Naive Individuals. Clin Infect Dis 58: 1165-1173.
24. McConnell MJ, Mier-Mota J, Flor-Parra F, Martinez-Fernandez FJ, Lopez- Cortes LF, et al. (2011) Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level Viremia. Journal of Acquired Immune Deficiency Syndromes 58: 446-449.
25. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, et al. (2001) Prevalence and predictive value of intermittent viremia with combination hiv therapy. Jama 286: 171-179.
26. Mira JA, Macias J, Nogales C, Fernandez-Rivera J, Garcia-Garcia JA, et al. (2002) Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antiviral Therapy 7: 251-256.
27. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, et al. (2002) Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 16: 2035-2041.
28. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, et al. (2005) Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clinical Infectious Diseases 41: 1326-1332.
29. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ (2007) Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 196: 1773-1778.
30. Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, et al. (2005) HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. Aids 19: 1065-1069.
31. Ibrahim KY, Recordon-Pinson P, Malvy D, Fleury H, Segurado AC (2012) Intermittent HIV-1 viremia (Blips) and virological failure in a cohort of people living with HIV from Sao Paulo, Brazil. AIDS Patient Care and STDs 26: 512-515.
32. Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, et al. (2002) The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to ,400 copies/ml. Aids 16: 1521-1527.
33. Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, et al. (2005) Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol 33: 75-78.
34. Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, et al. (2012) Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 205: 1230-1238.
35. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, et al. (2012) Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAARTTreated Patients and Risk of Virological Failure. J Acquir Immune Defic Syndr 60: 473-482.
36. Alvarez Estevez M, Chueca Porcuna N, Guillot Suay V, Pena Monge A, Garcia Garcia F, et al. (2013) Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to .50 copies per milliliter. J Clin Microbiol 51: 1555-1557.
37. Pugliese P, Delpierre C, Cuzin L, Poizot-Martin I, Rey D, et al. (2013) An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. HIV Medicine 14: 509-515.
38. Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, et al. (2011) Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 67: 213-217.
39. Charpentier C, Landman R, Laouenan C, Joly V, Hamet G, et al. (2012) Persistent low-level HIV-1 RNA between 20 and 50 copies/ML in antiretroviral- treated patients: Associated factors and virological outcome. Journal of Antimicrobial Chemotherapy 67: 2231-2235.